NEW YORK — A once-daily fixed dose of Roclatan for patients with ocular hypertension or open-angle glaucoma demonstrated statistically significant IOP lowering compared with the drug’s individual components, according to a poster presented here of the 12-month data of the Mercury 1 study.
“This study demonstrated superiority at all nine time points up to the primary efficacy endpoint at month 3. It continued to maintain IOP lowering all the way to month 12,” Theresa Heah, MD, a co-author of the study, told Healio.com/OSN.
The Mercury 1 study was a randomized, 12-month,
Uncategorized